 | Up a level |
2022
Janning, M., Sueptitz, J., Albers-Leischner, C., Delpy, P., Tufman, A., Velthaus-Rusik, J-L, Reck, M., Jung, A., Kauffmann-Guerrero, D., Bonzheim, I, Braendlein, S., Hummel, H-D, Wiesweg, M., Schildhaus, H-U, Stratmann, J. A., Sebastian, M., Alt, J., Buth, J., Esposito, I, Berger, J., Toegel, L., Saalfeld, F. C., Wermke, M., Merkelbach-Bruse, S., Hillmer, A. M., Klauschen, F., Bokemeyer, C., Buettner, R., Wolf, J. and Loges, S. (2022). Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM). Ann. Oncol., 33 (6). S. 602 - 616. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2020
Frost, N., Christopoulos, P., Kauffmann-Guerrero, D., Stratmann, J. A., Riedel, R., Schaefer, M., Alt, J., Guetz, S., Brinkmann, J. and Griesinger, F. (2020). Lorlatinib in pretreated ALK/ROS1-positive non-small cell lung cancer (NSCLC): Results from the German early access program. Ann. Oncol., 31. S. S874 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2017
Stratmann, J. A., Hornetz, S., Griesinger, F., Wolf, J., Christoph, D. C., Sackmann, S., Spengler, W., Bischoff, H., Schaefer, M., Alt, J., Mlueller, A., Laack, E., Kimmich, M. and Sebastian, M. (2017). An expanded access program of osimertinib (Tagrisso) in patients with advanced non-small cell lung cancer: data report from Germany. Oncol. Res. Treat., 40. S. 170 - 171. BASEL: KARGER. ISSN 2296-5262